Category Archives: Stem Cell Doctors

[World Cancer Day] 5 women from Bollywood whose struggles with cancer are truly inspirational – YourStory

February 4 marks World Cancer Day and is designated to raise awareness of cancer and encourage its prevention, detection, and treatment. Battling cancer is tough, it alters your life but it's not the end. Cancer survivors are inspirations and a ray of hope for many others who are also battling the disease.

Cancer can be tougher on people who are in the limelight as they have to deal with intense public scrutiny. However, making the diagnosis public can have a positive effect on people, and help them in their battle against cancer.

(Top) Sonali Bendre, Lisa Ray, Tahira Kashyap; (Bottom) Nafisa Ali, Manisha Koirala.

In 2012, Manisha Koirala was diagnosed with late stage ovarian cancer. The actress of the Bombay and Dil Se fame writes about her struggle with the disease in her memoir, Healed: How Cancer Gave Me A New Life which was published in December 2018.

In it, she reveals that for over a decade she had abused her body and cancer taught her to lead a better lifestyle. Now, she hopes to promote the importance of preventive lifestyle and early detection.

She took a break from acting in 2012 and returned five years later with the coming-of-age drama Dear Maya, Netflix's Lust Stories and Sanju.

Lisa Ray was one of the first actresses to make her cancer diagnosis public. The Indo-Canadian actress had multiple myeloma, a cancer that affects white blood cells. She was diagnosed in 2009 and after a successful stem cell transplant, she announced that she was cancer free.

She has revealed that her diagnosis shocked her at first, which was then followed by denial. However, eventually she tried to transform the experience into something which could help others.

During her treatment, she used her blog The Yellow Diaries to post details of her treatment and pictures of her journey. She worked to remove the oppression and burden people try associating with the disease through her blog.

She has championed the cause of multiple myeloma, a little-known form of cancer and helped raise funds for its research. She has also supported other initiatives such as the Pantene Beautiful Lengths and the Multiple Myeloma M-Moving Together Toward The Cure Walk.

She even chronicled her life, love, and cancer experiences through sarees. The Ray of Hope saree collection in which each saree has a story behind it.

After being diagnosed with cancer in 2018, Sonali Bendre had an uphill battle with cancer. She was diagnosed with a "high-grade cancer" that had metastasized. The cancer had spread from the primary tumour to all over her abdomen.

On her husband Goldie Behls insistence, she sought treatment in New York. Only after getting there, did the doctors inform her thatshe had stage IV cancer and had only a 30 percent chance of survival.

The actress took to Twitter to share her diagnosis and used social media to document her cancer journey.

Filmmaker and writer Tahira Kashyap was diagnosed with pre-invasive breast cancer in September 2018. She was detected with DCIS - ductal carcinoma in situ - in her right breast with high grade malignant cells. She underwent a mastectomy procedure to surgically remove her breasts.

She has revealed that she was not ready to share it with the world. However, she decided that her making the diagnosis public would help remove the stigma and taboo associated with cancer. She is now spreading awareness about early breast cancer detection awareness and is sparing no medium to take it forward.

The yesteryear actress, Nafisa Ali Sodhi was diagnosed with stage 3 peritoneal and ovarian cancer. The politician and activist was diagnosed in 2018 and used Instagram to share health updates with people to raise awareness for the need for early diagnosis. Diagnosed at the age of 60, she has now turned into a crusader for early detection of cancer, especially among women. She has featured in films such as Junoon, Major Saab, Bewafaa , Life In A... Metro and Yamla Pagla Deewana.

(Edited by Rekha Balakrishnan)

Read more from the original source:
[World Cancer Day] 5 women from Bollywood whose struggles with cancer are truly inspirational - YourStory

Son to shave head to support mum with leukaemia – Chronicle

WITH his mum being treated for leukaemia, Sana McFarlane-Smith is participating in the World's Greatest shave.

Sana's mother, Neda Master, was diagnosed with multiple myeloma, a cancer of the plasma cells, in April 2019.

Since then she has undergone months of chemotherapy treatment and a stem cell transplant.

Neda said when she first got her diagnoses she was relieved.

It had been a long process with lots of tests and scans, and she was grateful to finally know what was wrong.

"I was so sick of people telling me it was in my head. I didn't cry, I was relieved," Neda said.

"The 16 weeks of chemo was easy, but I got scared when they did they stem cell collection- that was a bit rough.

"You will feel fear, the stem cell process is not nice and the nurses are honest with you.

"I had wonderful doctors, and I wouldn't be here without them.

"When I went through the stem cell transplant it was very challenging for me - the pain, the nausea.

"I kept thinking 'am I going to get through this?'"

Neda is due to go through her second stem cell transplant this month, which will hopefully put her into remission.

Sana said he hoped to raise $15,000 for the Leukaemia Foundation.

"The reason I chose to fundraise for the World's Greatest Shave is because I'm currently doing a challenge which is the Duke of Edinburgh award," Sana said.

"One of the components is a form of service or volunteer work where you give back to the community.

"Since my mum was diagnosed with cancer and the Leukaemia Foundation has given so much to me, my mum and our family, I thought it would only be fair that I return the favour and give something to them."

The 16 year old said he wanted to be an oncologist or haematologist when he finished school.

To help support Sana's fundraising efforts, visit https://secure.leukaemiafoundation.org.au/registrant/FundraisingPage.aspx?RegistrationID=774634

Excerpt from:
Son to shave head to support mum with leukaemia - Chronicle

Meet the 21-year-old who turned her love for animals into a successful petcare business – YourStory

Once a pet rescuer, forever a pet lover.

Twenty-one-year-old Anushka Iyers journey as a pet parent and the Founder and CEO of petcare startup Wiggles started on somewhat similar notes. It was around October 2018, and Anushka, who had always been keen on the state of pet healthcare (preventive petcare, to be more specific) in India, was busy planning a trip to the Blue Cross, an animal welfare charity.

Team Wiggles

The Blue Cross visit turned out to be an experience that she wouldnt forget. The state of petcare in India is beyond miserable. Millions of stray dogs survive on the streets of the country, according to HelpAnimalsIndia.org, and most happen to be abandoned pets.

Ignorance amongst pet owners about preventive pet healthcare often leads to high vet costs and finally abandonment, since its marred by information asymmetry and access to personalised products, she says.

To address this ignorance and petcare knowledge among first-time and seasoned pet parents, Anushka launched Wiggles in December 2018 along with her father Rajh Iyer and Co-founder Venky Mahadevan.

The Pune-based startups goal is simple: to introduce transparency associated with costs, medication, nutrition, and wellness options across the pet industry.

The platforms flagship offering is theWiggles Box, a monthly preventive healthcare subscription box that contains anti-parasitic medicines, nutritional products, and essential vitamins for pets.

This offering is further complemented with personalised alerts to ensure you never miss your pets supplement dosage. The subscription-based curated healthcare product box, however, is just one part of the three-pronged approach followed by the company. Vet-on-call and grooming services form the other two pillars of its services.

The grooming services have been created keeping in mind simplicity, affordability, and convenience for pets, and start at Rs 799. Apart from this, Wiggles has annual healthcare plans that ensure consistent vet and grooming visits every month along with basic and mandatory vaccines, tests etc. covered and done by us right when it has to be done.

The companys portfolio also includes a range of 18 petcare products curated keeping in mind the pain points of a first-time pet parent.

Indias pet care market, riding on growing disposable income and increasing humanisation of pets, continues to record double-digit growth. A trend that has, unsurprisingly, grabbed eyeballs of the investors and new players alike.

Many pet startups such as Heads Up for Tails, PetKonnect, Petcart, and Woofwoofnow have come up in recent years, claiming to solve one or the other pet-related concern. What this multi-player market has failed to achieve, however, is a personalised approach towards pet healthcare.

Right now this market is ripe for disruption since one size does not fit all, and every dog needs a personalised healthcare plan.

With this vision, Wiggles has set out to take a stronghold of the direct-to-consumer petcare market by administering a definitive first-mover advantage. We are not reinventing the wheel here, but manufacturingOTC products, keeping in mind simplicity, affordability and convenience, the founder says.

Currently a team of 72, most of whom are either pet parents or pet lovers, Wiggles is available on ecommerce platforms like Amazon, Flipkart, BigBasket, and Dunzo. Aimed at spreading awareness about preventive pet healthcare, the platform will soon launch the Wiggles App to simplify pet healthcare further.

In November 2019, Wiggles took the first step towards strengthening its presence, operations, distribution, and expanding its product range.

The petcare startup raised angel funding of $1 million from a clutch of high net-worth (HNI) individuals. The participating investors included Nachikhet Deshpande, COO of L&T Infotech; Aparna Badkundri, Director, Dell Computers; Sachin Phadke, MD of Vetbiochem India; Abhay Amrute, Senior Partner, IIFL Wealth Management Ltd; Satish Billakota, VP, Europe Cognizant; and Risshee Tandulwadkar, Founder, Solo Stem Cell Clinic.

The plan of taking Wiggles to all major Indian cities, however, is a vision marked by several key milestones, one of them being the moment they got their drug licence.

When we decided to create our own range of products, we were told by almost everyone that it would take months to acquire the licence and we were falling off track. However, we were relentless, and we received it in 24 days, the entrepreneur recalls.

In fact, Anushkas biggest milestone is also something that has, in a way, shaped her entire entrepreneurial journey, even lending the name for her startup: her own pet, Wiggles.

(Edited by Teja Lele Desai)

Read the original:
Meet the 21-year-old who turned her love for animals into a successful petcare business - YourStory

On Holocaust Remembrance Day, the stories of two Jewish scientists – Massive Science

The 2019 novel coronavirus (2019-nCoV) outbreak has sparked a speedy response, with scientists, physicians, and front-line healthcare professionals analyzing data in real-time in order to share findings and call out misinformation. Today, The Lancet published two new peer-reviewed studies: one which found that the new coronavirus is genetically distinct from human SARS and MERS, related viruses which caused their own outbreaks, and a second which reports clinical observations of 99 individuals with 2019-nCoV.

The first cases of the coronavirus outbreak were reported in late December 2019. In this new study, Nanshan Chen and colleagues analyzed available clinical, demographic, and laboratory data for 99 confirmed coronavirus cases at the Wuhan Jinyintan Hospital between Jan 1 to Jan 20, 2020, with clinical outcomes followed until 25th January.

Chen and colleagues reported that the average age of the 99 individuals with 2019-nCoV is around 55.5 years, where 51 have additional chronic conditions, including cardiovascular and cerebrovascular (blood flow to the brain) diseases. Clinical features of the 2019-nCoV include a fever, cough, shortness of breath, headaches, and a sore throat. 17 individuals went on to develop acute respiratory distress syndrome, resulting in death by multiple organ failure in 11 individuals. However, it is important to note here that most of the 2019-nCoV cases were treated with antivirals (75 individuals), antibiotics (70) and oxygen therapy (75), with promising prognoses, where 31 individuals were discharged as of 25th January.

Based on this sample, the study suggests that the 2019 coronavirus is more likely to affect older men already living with chronic conditions but as this study only includes 99 individuals with confirmed cases, it may not present a complete picture of the outbreak. As of right now, there are over 6,000 confirmed coronavirus cases reported, where a total of 126 individuals have recovered, and 133 have died.

In a second Lancet study, Roujian Lu and their fellow colleagues carried out DNA sequencing on samples, obtained from either a throat swab or bronchoalveolar lavage fluids, from eight individuals who had visited the Huanan seafood market in Wuhan, China, and one individual who stayed in a hotel near the market. Upon sequencing the coronaviruss genome, the researchers carried out phylogenetic analysis to narrow down the viruss likely evolutionary origin, and homology modelling to explore the virus receptor-binding properties.

Lu and their fellow colleagues found that the 2019-nCoV genome sequences obtained from the nine patients were very similar (>99.98% similarity). Upon comparing the genome to other coronaviruses (like SARS), the researchers found that the 2019-nCoV is more closely related (~87% similarity) to two bat-derived SARS-like coronaviruses, but does not have as high genetic similarity to known human-infecting coronaviruses, including the SARS-CoV (~79%) orMiddle Eastern Respiratory Syndrome (MERS) CoV (~50%).

The study also found that the 2019-nCoV has a similar receptor-binding structure like that of SARS-CoV, though there are small differences in certain areas. This suggests that like the SARS-CoV, the 2019-nCoV may use the same receptor (called ACE2) to enter cells, though confirmation is still needed.

Finally, phylogenetic analysis found that the 2019-nCoV belongs to the Betacoronavirus family the same category that bat-derived coronaviruses fall into suggesting that bats may indeed be the 2019-nCoV reservoir. However, the researchers note that most bat species are hibernating in late December, and that no bats were being sold at the Huanan seafood market, suggesting that while bats may be the initial host, there may have been a secondary animal species which transmitted the 2019-nCoV between bats and humans.

Its clear that we can expect new findings from the research community in the coming days as scientists attempt to narrow down the source of the 2019-nCoV.

Read the original here:
On Holocaust Remembrance Day, the stories of two Jewish scientists - Massive Science

Lessons Learned on Listening to the Dying, World Cancer Day Reflections – MissionsBox

World Cancer Day 2020 by Karen Burton Mains

Years ago, traveling around the world in the role of a journalist at the invitation of the director of an international relief organization, we stopped to visit Mother Theresas Kalighat Home for the Destitute Dying. I will always remember, as have other journalists before me, particularly Malcolm Muggeridge, the soft light that embraced the building and the unusual peace. The calm in the eyes of the Sisters of Charity. The rows of cots with emaciated bodies on them. Brown eyes looking into the distance. The feeling of being poised at some edge. Mostly, I remember the enfolding light. The light.

By the time our son, Jeremy Mains, was rushed to the local hospitals emergency room, his bone marrow was filled with cancer cells. I noticed that April of 2013 that he had seemed unusually tired, but I chalked it up to holding down several part-time jobs and being a highly involved father of three small children, which entailed sharing home responsibilities with a working wife.

However, when the GP phoned Angela with an urgent message that bloodwork results indicated that Jeremy should go immediately to Central DuPage Hospitals ER, our son had already been admitted, his kidneys shutting down. He was quickly diagnosed as suffering from an acute form of a rare lymphoma. Quickly, he was transferred to the oncology unit of Rush University Medical Center in downtown Chicago.

I wish I had read Atul Gawandes Being Mortal before our son, Jeremy, died at age 41 of acute blastic mantle-cell lymphoma. Gawandes book is subtitled Medicine and What Matters in the End and is a practicing surgeons deeply affecting journey into examining how medicine can do better facilitating the last months, weeks, days and minutes of a patients life.

In order to write about this topic well, Gawande follows a hospice nurse on her rounds, visits with a geriatrician in his clinic and dialogues with people reforming nursing-home practices. Then he interviews patients and the elderly as to how they want to frame their last days. His conclusions are pertinent for all who face end-of-life scenarios, whether through disease or old age.

Gawande writes,

Two-thirds of terminal cancer patients in the Coping With Cancer study reported having no discussion with their doctors about their goals for end-of-life care despite being, on average, just four months for death. But the third who did have discussions were far less likely to undergo cardiopulmonary resuscitation or be put on a ventilator or end up in an intensive care unit. Most of them chose hospice. They suffered less, were physically more capable, and were better able, for a longer period, to interact with others.[1]

At this time, I and a handful of friends, all of us with decades of ministry experience behind us, were testing the concept of listening groups. Eventually, over the course of eight years, I would lead some 250 listening groups, the majority with three to four participants, meeting once a month over seven months. The listening groups were trialed in various other settingsone a weekend retreat with 90 attendees; another, a group of 26 people we took on a tour to France. A pastor friend experimented using the listening-group model with his church staffwith great success, he reported to me. The architecture of the listening groups that my friends and I were testing surprised us with how quickly the group members felt safe with one another.

The format was built around a listening structure that ensured space and time enough for each of the participants to feel not only heard but understood. A gentle discipline maintained that the response to each one who shared could only be in the form of a question, and that could be asked only when the person sharing was finished with what he/she wished to say. This eliminated the distresses many small groups facea dominant personality, for instance, or sermonettes that interrupt the individuals own capacity to analyze and determine their own paths to maturation. We even forbid the well-intended-but-interrupting, Oh, let me pray for you. I watched, often in surprise, at the development of this deepening capacity of the participants to hear and be heard, which appeared to result in measurable and unusually rapid personal growth.

Listening to your son, however, who has been given a diagnosis that most likely will be terminal, is another matter altogether. A dedicated team of oncologists at Rush University Medical Center in Chicago, headed by Dr. Parameswaran Venugopal, the head of the cancer unit (where Jeremy spent practically all of the last few months of his life), designed a strong chemotherapy-and-radiation treatment course with an accompanying pharmaceutical regimen. Our son was young (41 years old) and healthy (once the kidney failure had been reversed). Plus, he was determined to live. Because of all this, there was a slim chance of Jeremy beating the odds.

Rough notes in my quick-scrawl handwritingalmost unreadable even to meindicated that on June 10, in room 1058 of the ICU, Dr. Stephanie Christiansen walked us through the progress of his disease. I wrote in my notebook:

Blastic mantle cell lymphoma. Burkitt cell lymphoma. Blastic = immature white cells. Mass in colon/not typical. STAGE FOUR. Lymphoma.org. Mantle cell is slow growing. Lots of variations. Treatments (1) Chemotherapy/HyperCVac given in cycles of 3 or 4 days, up to 8 cycles. Cycle A drug regimen. Infection. White counts are low[indecipherable word](something?) count every day. Stem cell transfusion.

Perhaps this erratic series of words and phrases gives a sense of how confusing cancer-cell diagnosis and treatment can be to the average family member. Angela, Jeremys wife, was persistent in achieving a laypersons understanding. I tried to grasp what I could, but basically found myself deferring to her determined comprehension.

One day, thinking to myself, If I ever want to write about this, I need to keep better records, I looked over a medical page given us by the hospital staff. The headline was CYTOTOXIC / HAZARDOUS MEDICATION ORDER. At my request, a kind nurse pulled the website description of some of the drugs in Jeremys regimen. She also printed me off a copy of the HyperCVad A regime. The drugs listed were: Aloprim, used for stopping high uric acid levels during chemo; dexamethasone; used to treat leukemia and lymphoma; ondansetron, used to stop upset stomach and throwing up; Mesna, used to lower the bad effects of some cancer drugs on the bladder; doxorubicin, used to treat cancer, leukemia and lymphoma; and Vincristine, used to treat leukemia, lymphoma and cancer. These were only for the beginning stages of Jeremys pharmaceutical regimen.

I wont list all the negative side-effects each individual drug is capable of causing. All the printouts for each drug, often four pages long, however, include this question: What are some side effects that I need to call my doctor about right away? Then in caps: WARNING / CAUTION.

What follows on each page is a list comparable to the TV pharmaceutical ads where a narrator breathlessly races through possible detrimental responses from the drug the advertisement has just touted as a near-miracle cure. This voiceover invariably accompanies a visual montage of happy people being healed of whatever ailment. Or if not a cure, there are, at least, tantalizing promises of renewed health and vigor, well-being (inferred by the smiles and satisfaction on the actors faces) and some physical outcome that is much, much better than the other competitive drug on the market. Inevitably, somewhere in that rushed half-whispered cacophony of possible side effects, the phrase that can possibly result in death usually occur. The truth is this: There is almost no drug you put into your body that wont cause side effects, eventually, of some kind.

In these early days of treatment, Jeremy, with his wry sense of humor, noted that he had been warned that nausea and diarrhea would be side effects of the chemo: But no one told me I would explode from both ends at the same time! That night before this observation he had lain for some time, exhausted, on his hospital bathroom floor before a nurse found him. Chemo treatments are basically a controlled poisoning of the body.

My instinctpurely a personal uninformed lay opinion, most non-scientific to be sure, and one from a mother watching her child die a gruesome deathis this: One day we are going to look back, like we do now on the Greek physician Galens concept of four humors in the blood and the practice of bloodletting and purging and say, You mean they used to treat cancer by poisoning the body? And the treatment was often as dangerous as the disease?! How barbaric! I feel this in my bones (or perhaps I should say in my genes, since at this time gene manipulation is one of the possible cancer-cure frontiers). Still, I bow before the fact that chemotherapy and surgery are curatives for many cancers in many stages, and I understand that the knowledge to cure evolves in countless laboratories, scattered research centers and across the hospital wards of many countries. Sometimes cures take decades, even centuries, to discover.

Somewhere in this first month, Jeremy said to me, Mom, I dont know if I can do this. To my sons private confession of weakness, I shot back, Of course you can. And no wonder I reacted: We were only one month into the horror that is the cancer journey. Despite its ubiquitous presence in our modern world, for the patients and their families who succumb to the diseaseand believe me, this is a family affairwe were all impacted beyond our capacity to absorb and understand. Societal familiarityover 500,000 people die of cancers every year in the U.S.does not translate to personal capability when faced with this diagnosis in your own family.

Instead of my instinctive buck-up retort, I should, instead, have asked those gentle questions drawn from my experience with the listening groups and my consequent research into what happens in the brain when someone feels listening to and understood. I get it. Sometimes I dont know if any of us are going to get through all this. Tell me what youre thinking and what you are feeling.

The battle of being mortal is the battle to maintain the integrity of ones life, writes Dr. Gawande, to avoid becoming so diminished or dissipated or subjugated that who you are becomes disconnected from who you were or who you want to be. Sickness and old age make the struggle hard enough.[2] In every way through those months of hospitalization, I watched my son become diminished and dissipated and subjugated and disconnected. To my great regret, I did not offer my son this opportunity of end-of-life discussions. Though my grief at losing a child was and is still a clean griefthere was no breach in relationship, no sorrows of alienation o displeasure with each otherI do wish I had read Being Mortal before Jeremy died. Gawandes remarkable book was released in 2014; Jeremy died the year before.

So, the team of oncologists, headed by Dr. Venugopal, valiantly designed treatments, the goals of which were to bring the active cancer into remission, to keep the toxicity manageable, and to find a donor for a bone-marrow transplant. Jeremys oldest brother, Randall, was a perfect match, but that life-supporting treatment was not to be.

I watched as the whole hospital system moved in concentrated efficiency to preserve my sons life. Siddhartha Mukherjee, writing about leukemia, captures this medical momentum beautifully in his Pulitzer Prize-winning book The Emperor of All Maladies:

The arrival of a patient with acute leukemia still sends a shiver down the hospitals spineall the way from the cancer wards on its upper floors to the clinical laboratories buried deep in the basement. Its pace, its acuity, its breathtaking, inexorable arc of growth forces rapid, often drastic decisions; it is terrifying to observe, and terrifying to treat. The body invaded by leukemia is pushed to its brittle physiological limitevery system, heart, lung, blood, working at the knife-edge of its performance.[3]

This describes exactly what I observed about the medical teams working around our son.

Jeremy did go into remission, which Dr. Venugopal described to Angela as a miracle. But the treatment was so toxic to his system that he had no capabilities to fight off the highly contagious and antibiotic-resistant staph infection MRSAin medical terminology, Methicillin-resistant Staphylococcus aureusa potential killer for the immune system-deficient. Though present in general society, ironically it particularly loves to lurk in hospitals.

Jeremy succumbed to waves of infection. Ironically, the very PICC line inserted in a vein on his chest closer to his heart so intravenous treatments could be administered was the very source of many of these infections. Soon, Jeremys mouth and face became paralyzed. He couldnt eat, was fed through stomach tubes, his words were bumbled, and in truth, after the chemotherapy treatments, at least to my viewpoint, there was not one day when he was better than the day before.

Nor do I know, apart from Jeremys wife Angela, if any one on that whole oncology team, from nurses, to teaching fellows, to the head of the hematology department, to the social workers, to the visiting pastors, ever talked to Jeremy about what was important to him as far as how he wanted to die. This I do know: Our son basically spent the last five months of his life, going from debilitating physical crisis to demeaning physical incapability, longing to be home with his wife and three small children; Eliana age six, Nehemiah age three and the baby, Anelise, age six months. And he wanted to be home on his own terms, anyway, anyhow.

(Lest I forget, let me also mention the two English Bulldogs, Roxie and dArtagnan, from whom, during his few brief days at home, Jer also refused to be separated.)

Gawande makes it clear that a listening process is paramountone in which sensitive questions are asked of the patient as far as what kind of attention attendants and family should be giving to those near death. (This must be a situation in which the medical profession does not do all the talking, however, but learns to listen and to be patient in the listening processquite a stretch for most knowledgeable folk in any field.) He assesses the deficiencies of retirement and nursing home environments:

This is the consequence of a society that faces the final phase of the human life cycle by trying not to think about it. We end up with institutions that address any number of societal goalsfrom freeing up hospital beds to taking the burdens off families hands to coping with poverty among the elderlybut never the goal that matters to the people who reside in them: how to make life worth living when were weak and frail and cant fend for ourselves.[4]

Being Mortal takes a stunning turn into the personal when the writers father, Atmaram Gawande, a well-respected and successful surgeon himself, succumbs to cancer. The doctor/son realized that with all the research he had conducted on listening to those in end-of-life scenarios, and with all the insights he had achieved, it was most difficult to apply those principles to his own father. His medical training, his save-and-preserve-life mentality swooped in and crowded out empathy, driving him to find a cure, to perform some sort of intervention. Believe me, I understand.

The problem with medicine and the institutions it has spawned for the care of the sick and the old is not that they have had any incorrect view of what makes life significant, Gawande writes.

The problem is that they have had almost no view of it at all. Medicines focus is narrow. Medical professionals concentrate on repair of health, not sustenance of the soul. Yetand this is the painful paradoxwe have decided that they should be the ones who largely define how we live in our waning days This experiment has failed.[5]

The next death we go through as a family, if we have any choice at all, will not be done this way. Our son, brilliant and gifted, a multicultural specialist, an adjunct professor teaching college Spanish and who also was functional in conversational Mandarin, this young man with his own immigration counseling service who had achieved the skills and grasp of a paralegal, this funny and compassionate and intriguing young man, died a gruesome death. I shudder even now as I think about it.

Still, before toxicity blasted his nervous system and his mouth became paralyzed (closed for months, then frozen open before he died), this young man, our son, in the early stages of his own death, taught me to listen to the dying. He determined that the long hours spent on my shift would be devoted to catching me up on my woeful ignorance of popular music, or as his teasing explanation defined it, That would be the last fifty years of music history, Mom. His sly gotcha glance was only made more roguish by his drooping face. My father, after all, had been the director of the music department of Moody Bible Institutehardly a bastion of contemporary cultural musicology. I was raised in a home where the emphasis was onguess what?church music. Worship services. Choir practices on Thursday nights. Youth choir rehearsals on Sunday afternoons. Worship services. Sunday night signs. Candlelight carols. Easter cantatas.

Using his iPad to pull down samples from Pandora, I then realized Jeremy was looking at our study not so much as a pop-culture aficionado but through the understanding of an ethnomusicologist. There was no one I would rather have traveled around the world with as a guide than Jeremy. In high school, he found a native speaker to tutor him in Japanese and took himself off to Japan at age 16 for a summer of foreign culture and a conversational-language plunge. While in college and at his instigation, Jeremy met me at the Art Institute of Chicago to view an exhibit of ancient Japanese kimonos. This private gallery tour gave me a hint that this son was a compulsively curious scholar, a lifelong learner. He knew the styles and ages of the kimonos without looking at the wall plaques. It was here I learned about the Edo period between 1603 and 1868 under the rule of the Tokugawa shogunate, the last military feudal government. I also received an additional short and unasked-for briefing on the demise of the samurai.

Let us next move to China, where Jeremy lived and taught for a cumulative total of three yearstwo years before he and Angela wed and one after. Need to know about the Shang Dynasty? (Approximate duration? 16001000 B.C.). How about the Ming Dynasty? What about the Boxer Rebellion? Before visiting him for a month in the middle of his two-year teaching contract at the Petroleum Institute in the city of Nanchong, Sichuan Province, we were emailed a full reading list to study before embarking. Certainly, it was the equivalent of a college semester of learning.

Jeremy kept records by printing pertinent ideas in small black notebooks, those wrapped with black elastic bands. So, with his determination not to waste the hospital hours, still lying in bed, and with me, a captive student at hand, spending hours, sometimes day and all-night shifts, he introduced me to the American Music Idiom 101. The black books came out, then the iPod. It didnt take me long (probably on a train ride from the Chicago back to the suburbs) to realize I was being privately tutored in a spontaneous course in ethnomusicology. Initially, that was the study anthropologists made of non-Western music and the cultures and environments and customs that gave rise to them. Eventually, attention was turned toward Western music as well. In short, ethnomusicology has been described as the study of people making music. This is exactly what this son opened up for mehe helped me to understand contemporary popular music as a means to identify with the people who had either made or were now making it.

Totally unprepared for the learning curve ahead, seeking at first only to console a gravely ill son, to help assuage the boredom of long hours, to divert attention from the constant tests and blood draws and the impossible difficulty of swallowing pills (even before his mouth became frozen, when kind nurses crushed all the tablets, and even then the taste was so bitter he had difficulty), I began one of the most profound listening experiences of my life. Admittedly, my literacy in popular music consisted of the infrequent songs I heard that others were listening to, or occasional snatches of the tuning dial while drivingthe oldies radio station in Chicago, 94.7. The learning was delightful, and I began to see that much of popular music was a cry from the mean streets, sung evidence, in many cases, of what we faith-based folk consider true lostness; I am deeply grateful for the exposure. I learned to listen to the words and rhythms of another kind of dying in that hospital room of my dying child.

As a result of the early chemo rounds when an Ommaya Reservoir had been implanted in his skull to enable the toxic intrathecal brain drips, and because of this procedure, a bilateral droop developed, paralyzing a side of Jeremys face and his mouth. It became an excruciating exercise to catch what our son was attempting to say since the consonants b, d, f, m, n, p, v and w were unpronounceable. Sometimes Jeremy would actually press his lips together with his fingers to make the puffing effort for any of these sounds.

Of course, if asked, I would have made the decision to give my life for his in an instant. I would have made the decision for this exchange with such fierce love, such terrible tenderness and without a moments hesitation. But that was not a choice at hand for any of us who loved him. But what I could have done I wish I had done. I regret not opening up those conversations about life and its meaning, about death and its coming possibility. If death is facing you, my dear son, how do you want to frame your last days?

There is a curious thing about death, at least for me: The dead are not forgotten. Those we have known in love exist in flashes of vivid understanding after they are gone. My father died when I was 35, my mother when I was 39. The essence of who they were lives on in merarely a day goes by that I dont think of them. I am now in my 70s. We, the living, assess the meaning of the lives of loved ones now dead in ways we would never do had they still been living. We tell remember-when stories, and we often pause to analyze the impact of those family events in a way we do not if participants were still alive. Remember the working trip we took together in the Caribbean? What was your favorite part of the trip to Europe? Do you remember how you took on your dad when we arrived in Beijing? (As Jeremy was bartering with Chinese taxi-drivers at the airport after our long flight from the States, David, weary and jet-lagged protested, Jer, just get a cab, any cab. Jeremy asked, Do you speak Mandarin? Or is it I who speaks Mandarin? Point made.)

I am still processing the meaning of my sons life and of his death. What have I learned from him? What should I change about the way I approach the days aheadthose days of living and the inevitable days of dying? I have learned this muchone lesson among the manyDavid and I are saying to one another, my husband and I, Let us talk together about dying. Let us listen deeply to each other and learn what will make the passage from this world to the next bearable, compassionate and as much as possible for our offspring, considerate.

I do probably have some papillary cancer floating around in the cells of my own body. A cancerous thyroid was removed from my throat five months after Jeremys death. It is a slow-growing cancer. So, my wish at this almost octogenarian age is this: Should that cancer flourish and thrive, let me die. I dont want at this stage to go through the debilities and excruciating treatments of this current time. I have lived a rich and good life. Four beautiful children. Nine delightful grandchildren. A fruitful and meaningful marriage of some 59 years. A circle of friends. A deep and sustaining faith in God and His Son Jesus Christ. Travel to some 55 countries in the world. Board work with crucial faith-based development organization with corporate missions I was proud to serve. The accomplishment of writing twenty-some books.

This, apart from a magical plunge into ethnomusicology, is another of the lessons about dying I learned from a dying son. Living ends. We cannot always determine when or how that will happen. Yet, in small and remarkable ways, we can ready ourselves for that terminal status. We can be clear, apart from the freak and indubitable accidental, about how it is we want to die. That is not a morbid choice, to talk about our own deaths. End-of-life conversations are paramount to passing well. They fit into the Scriptural discourse of the Apostle Paul,

For I am already being poured out like a drink offering, and the time has come for my departure. I have fought the good fight, I have finished the race, I have kept the faith. Now there is in store for me the crown of righteousness, which the Lord, the righteous Judge, will award to me on that dayand not only to me, but also to all who have longed for his appearing. 2 Timothy 4:67.

I miss my son. Miss him every day. But then, I too am close. I am close.

Footnotes:

To read more news on World Cancer Day on Missions Box, go here.

For another blog on Patheos by Karen Burton Mains, go here.

For more blogs on Patheos by Gospel for Asia, go here.

Go here to read the rest:
Lessons Learned on Listening to the Dying, World Cancer Day Reflections - MissionsBox

Stem Cell Therapy Market Predicted to Accelerate the Growth by 2017-2025 – Jewish Life News

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the MarketCLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read the rest here:
Stem Cell Therapy Market Predicted to Accelerate the Growth by 2017-2025 - Jewish Life News

Snake venom can now be made in a lab and that could save many lives – KTVZ

If youre unlucky enough to have a poisonous snake sink its fangs into you, your best hope is an antivenom, which has been made in the same way since Victorian times.

It involves milking snake venom by hand and injecting it into horses or other animals in small doses to evoke an immune response. The animals blood is drawn and purified to obtain antibodies that act against the venom.

Producing antivenom in this way can get messy, not to mention dangerous. The process is error prone, laborious and the finished serum can result in serious side effects.

Experts have long called for better ways to treat snake bites, which kill some 200 people a day.

Now finally scientists are applying stem cell research and genome mapping to this long-ignored field of research. They hope it will bring antivenom production into the 21st Century and ultimately save thousands, if not hundreds of thousands, of lives each year.

Researchers in the Netherlands have created venom-producing glands from the Cape Coral Snake and eight other snake species in the lab, using stem cells. The toxins produced by the miniature 3-D replicas of snake glands are all but identical to the snakes venom, the team announced Thursday.

In a parallel breakthrough, scientists in India have sequenced the genome of the Indian cobra, one of the countrys big four snakes that are responsible for most of the 50,000 snakebite deaths India sees a year.

Theyve really moved the game on, said Nick Cammack, head of the snakebite team at UK medical research charity Wellcome. These are massive developments because its bringing 2020 science into a field thats been neglected.

Hans Clevers, the principal investigator at the Hubrecht Institute for Developmental Biology and Stem Cell Research in Utrecht, never expected to be using his lab to make snake venom.

A decade ago, he invented the technique to make human organoids miniature organs made from the stem cells of individual patients. Theyve allowed doctors to test the specific effects of drugs safely outside the body, something that has revolutionized and personalized areas such as cancer treatment.

So why did he decide to culture a snake venom gland?

Clevers said it was essentially a whim of three PhD students working in his lab whod grown bored of reproducing mouse and human kidneys, livers and guts. I think they sat down and asked themselves what is the most iconic animal we can culture? Not human or mouse. They said its got to be the snake. The snake venom gland.

They assumed that snakes would have stem cells the same way mice and humans have stems cells but nobody had ever investigated this, said Clevers.

After sourcing some fertilized snake eggs from a dealer, the researchers found they were able to take a tiny chunk of snake tissue, containing stem cells, and nurture it in a dish with the same growth factor they used for human organoids albeit at a lower temperature to create the venom glands. And they found that these snake organoids tiny balls just one millimeter wide produced the same toxins as the snake venom.

Open them up and you have a lot of venom. As far as we can tell, its identical. Weve compared it directly to the venom from the same species of snake and we find the exact same components, said Clevers, who was an author of the paper that published in the journal Cell last week.

The team compared their lab-made venom with the real thing at the genetic level and in terms of function, finding that muscle cells stopped firing when exposed to their synthetic venom.

The current antivenoms available to us, produced in horses not humans, trigger relatively high rates of adverse reactions, which can be mild, like rash and itch, or more serious, like anaphylaxis. Its also expensive stuff. Wellcome estimate that one vial of antivenom costs $160, and a full course usually requires multiple vials.

Even if the people who need it can afford it most snakebite victims live in rural Asia and Africa the world has less than half of the antivenom stock it needs, according to Wellcome. Plus antivenoms have been developed for only around 60% of the worlds venomous snakes.

In this context, the new research could have far-reaching consequences, allowing scientists to create a biobank of snake gland organoids from the 600 or so venomous snake species that could be used to produce limitless amounts of snake venom in a lab, said Clevers.

The next step is to take all that knowledge and start investigating new antivenoms that take a more molecular approach, said Clevers.

To create an antivenom, genetic information and organoid technology could be used to make the specific venom components that cause the most harm and from them produce monoclonal antibodies, which mimic the bodys immune system, to fight the venom, a method already used in immunotherapy treatments for cancer and other diseases.

Its a great new way to work with venom in terms of developing new treatments and developing antivenom. Snakes are very difficult to look after, Cammack said, who was not involved with the research.

Clevers said his lab now plans to make venom gland organoids from the worlds 50 most venomous animals and they will share this biobank with researchers worldwide. At the moment, Clevers said they are able to produce the organoids at a rate of one a week.

But producing antivenom is not an area that pharmaceutical companies have traditionally been keen to invest in, Clevers said

Campaigners often describe snakebites as a hidden health crisis, with snakebites killing more people than prostrate cancer and cholera worldwide, Cammack said.

Theres no money in the countries that suffer. Dont underestimate how many people die. Sharks kill about 20 per year. Snakes kill 100,000 or 150,000, said Clevers.

Im a cancer researcher essentially and I am appalled by the difference in investment in cancer research and this research.

One challenge to making synthetic antivenom is the sheer complexity of how a snake disables its prey. Its venom contains several different components that have different effects.

Researchers in India have sequenced the genome of the Indian Cobra, in an attempt to decode the venom.

Published in the journal Nature Genetics earlier this month, its the most complete snake genome assembled and contains the genetic recipe for the snake venom, establishing the link between the snakes toxins and the genes that encode them. Its not a straightforward cocktail the team identified 19 genes out of 139 toxin genes as the ones responsible for causing harm in humans.

Its the first time a very medically important snake has been mapped in such detail, said Somasekar Seshagiri, president of SciGenom Research Foundation, a nonprofit research center in India.

It creates the blueprint of the snake and helps us get the information from the venom glands. Next, his team will map the genomes of the saw-scaled viper, the common krait and the Russells viper the rest of Indias big four. This could help make antivenom from the glands as it will be easier to identify the right proteins.

In tandem, both breakthroughs will also make it easier to discover whether some of the potent molecules contained in snake venom are themselves worth prospecting as drugs allowing snakes to make their mark on human health in a different way to how nature intended by saving lives.

Snake venom has been used to make drugs that treat hypertension (abnormally high blood pressure) and heart conditions such as angina.

As well as being scary, venom is amazingly useful, Seshagari said.

The rest is here:
Snake venom can now be made in a lab and that could save many lives - KTVZ

Colleagues are registering as donors and raising funds to help Trowbridge firefighter Guy Tadman and the charities supporting him – Wiltshire Times

A Trowbridge firefighter is hoping his battle against leukaemia will lead to other cancer sufferers receiving life-saving treatment.

Watch Manager Guy Tadman was diagnosed with acute myeloid leukaemia at the end of November and has spent most of the last two months in the Royal United Hospital in Bath.

He has just finished his second round of chemotherapy and is now awaiting a decision by his doctors about the next steps in his treatment. However, it seems most likely he will need a stem cell transplant, possibly via a partial match from a family member.

Guy said: Finding a good stem cell match is really difficult, so getting more people registered as potential donors improves the odds for everyone in the situation Im in.

"Im incredibly lucky to have so many friends and colleagues who want to help, and it would be amazing if one of them proved to be the golden ticket for someone with cancer.

The Fire Brigades Union is leading the push for donors, and dozens of Mr Tadmans colleagues from Trowbridge fire station and elsewhere in Dorset & Wiltshire Fire and Rescue Service have already registered to become donors with the charity DKMS at http://www.dkms.org.uk.

Kate Scott, from the FBU, said: Guy is a good friend to so many people in our service but also in the wider fire family.

"Everyone wants to step up and do something, and hopefully one of the new donors will be a match for him or someone else. "Were also encouraging people to contribute financially, as every new donor swab kit costs the charity 40.DWFRS road safety manager Christine Sharma has already raised 1,930 for the Bloodwise charity by going #DryforGuy in a sponsored dry January - 1,114 of this came from Pewsey fire station, who held a car wash on January 4, supported by colleagues from Marlborough.

Fundraising events, including car washes, a ladder climb and an equipment carry challenge, are being planned across the service in support of the charities helping Guy and his family.

Read more here:
Colleagues are registering as donors and raising funds to help Trowbridge firefighter Guy Tadman and the charities supporting him - Wiltshire Times

If you want to ban fetal tissue research, sign a pledge to refuse its benefits – USA TODAY

Irving Weissman and Joseph McCune, Opinion contributors Published 7:00 a.m. ET Jan. 24, 2020

Severe Trump administration restrictions mean millions of Americans of all political and religious stripes won't benefit from fetal tissue research.

Last summer the Trump administration curtailed federal funding of medical research using human fetal tissue; the new rulestook effect Oct. 1. More recently, the administration addedrestrictions that are even more severe.

Immediately, important work at two NIH-supported labs in Montana and California that are fighting the AIDS epidemic stopped because they were testing new medications against HIV using mice with human immune systems derived from human fetal tissue. In the near term, all National Institutes of Health (NIH) funding of research using fetal tissuewill likely cease.

More than 30years ago, we invented SCID-hu mice for biomedical research on diseases affecting humans, by implanting human fetal blood-forming and immune system tissuesinto mice whose immune systems had been silenced. The implanted immune tissues came from an aborted fetus, and allowed our otherwise immune-deficient mice to exist and be vulnerable to viruses that infect humans.

Tissues from living infants would not have worked;they are too far along in development and nearly impossible to obtain. This mouse model (and later versions of it) became the only living system, outside of a human, in which advanced therapies for diseases like AIDS and other viral infections could be evaluated before they were given to people.

Our work with human fetal tissue proceeded with the highest level of caution and vigilance. We received advice from bioethicists, clergyand government officials, which led to the establishment of strict guidelines that are still used today. No woman was asked or paid to terminate a pregnancy, the termination process was unaltered, and the women were asked for donation of the organs only after they had decided to terminate the pregnancy. Thus, obtaining the fetal tissue for medical research had no impact on ending pregnancies.

Since then, mice with transplanted human fetal tissues have been successfully used by scientists to identify blood stem cells and to devise treatments now availableor in clinical trialsfor cancer, various viral infections, Alzheimers disease, spinal cord injuries, and other diseases of the nervous system. Such diseases kill or cripple many Americans including pregnant women, fetusesand newborn infants. Many of them have only a short window of opportunity wherein a new therapy can treat them, and a delay can be fatal.

National Institutes of Health in Bethesda, Maryland, on Oct. 21, 2013.(Photo: *, Kyodo)

The Trump administration's new rules are tantamount to a funding ban. In academic labs, the experiments are done by students and fellows in training, and the new rules block any NIH-funded students or fellows from working with human fetal tissue. Those who imposed the banmust bear responsibility for the consequences: People will suffer and die for lack of adequate treatments.

Americans pay the price:Trump administration's 'scientific oppression' threatens US safety and innovation

At a December 2018 meeting at NIH,after hearing scientific evidence about alternative research methods such as the use of adult cells, experts concluded that the use of fetal tissue is uniquely valuable. Nonetheless, the administration severely restricted the use of fetal tissue, thereby denying millions of Americans the fruits of such research Americans of all political stripes, since deadly viruses and cancers do not care who you vote for.

These restrictions subvert the NIH mission, which is to advance medicine and protect the nations health. To the extent that it was motivated by the religious beliefs of those in charge, it bluntly transgresses the American principle of separation of church and state. As a result, both believers and non-believers will die.

Of course, all who take the Hippocratic Oathto "do no harm,"which includes all medical doctors, will always offer and deliver all types of therapies that are available.

Restricting science: Trump EPA's cynical 'transparency' ploy would set back pollution science and public health

However, we believe that thoseresponsible forthis de facto ban, and perhapsthose who agree with them, should personally accept its consequences. We challenge them tobe true to their beliefs. They should pledge to never accept any cancer therapy, any AIDS medication, any cardiac drug, any lung disease treatment, any Alzheimers therapy, or any other medical advance that was developed using fetal tissue including our mice. Its a long list, one that you can learn about from us here. Should this apply to you, be faithful and be bold: Take the pledge.

Irving Weissman is a Professor of Pathology and Developmental Biology and the Director of the Stanford Institute of Stem Cell Biology and Regenerative Medicine and Ludwig Center for Cancer Stem Cell at Stanford University School of Medicine. Joseph McCune is Professor Emeritus of Medicine from the Division of Experimental Medicine at the University of California, San Francisco. The views expressed here are solely their own.

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/opinion/2020/01/24/trump-fetal-tissue-research-ban-hurts-all-americans-column/4553379002/

See the original post:
If you want to ban fetal tissue research, sign a pledge to refuse its benefits - USA TODAY

Scots tot, 3, battling rare blood cancer to receive stem cell donations from anonymous American woman – The Scottish Sun

A TODDLER battling a rare form of blood cancer will receive life-changing stem cell, from a US donor.

Adeline Davidson, three, has been receiving weekly blood transfusions to keep her alive.

5

She has been diagnosed with myelodysplasia, an extremely rare form of blood cancer that affects only one in 250,000 children.

Doctors have now identified a donor assessed as a 9/10 match who is female and lives in the United States.

Under existing regulations, Adelines parents Stephanie and Jordan, from Alness, Easter Ross, will not be able to find out any more about the woman who could change their daughters life for at least two years after the transplant.

Mrs Davidson said news of the match, which came via the Anthony Nolan register she has personally encouraged many people to sign up to, was relayed to her by a consultant at the Queen Elizabeth Hospital in Glasgow.

She said: My mind was going crazy. All we know is that she is an American we know nothing more than that.

"You hear stories about people meeting their donors.

5

"The most mind-blowing thing for me is that this person who we dont know will pass on some of her DNA to Adeline.

Its good news but it does bring new anxieties.

"Our focus now is keeping Adeline away from bugs and infections. She needs to be healthy.

All being well Adeline, will be prepared for the transplant which can help restore the bodys ability to make blood cells next month and undergo the procedure in March.

5

Stephanie said: The support has been amazing. The messages we have got have been lovely and kept us going.

"It shows you there are good people out there. A lot of people say Im calm.

"It is what it is and you just need to keep a positive mind and be strong for her.

"Now its a waiting game.

There was another surprise for Adeline when she was invited aboard the Maersk Resilient oil rig, one of the giant landmarks dotting Invergordons shoreline.

5

Crew members seeking a worthy local cause for money they wished to donate had asked around on shore and been pointed in the Davidsons direction.

As well as the invitation for a tour of the rig capable of drilling to a depth of 30,000ft and sleeping 120 people Adeline was given a 1,000 donation on behalf of crew members.

The delighted youngster, who may be the youngest ever guest to have boarded the rig, relished the jaunt in the company of her mum and granny Lorraine, whose has also championed her cause on a number of fronts.

5

Stephanie Davidson said: It was brilliant, we got to see around the whole rig.

When they handed over a 1000 cheque, the family who face regular long overnight hospital trips to Glasgow were bowled over.

Ms Davidson said: We were not expecting that much."

NICE N STEAMY Moment randy Glasgow couple caught romping in flat above above Nice N Sleazy

TOT ATTACK Scots thug left baby with two broken arms because she wouldn't stop crying

Breaking

RUSH HOUR HORROR Man killed by 'machete-wielding' attacker in front of horrified commuters

Exclusive

THEY 'BROKE CODE' Furious gang crooks could grass on Cumbernauld gun killers who shot dog

VILE GANG Scots cops took down huge asylum seeker grooming gang - but kept it secret

ZOO SALE Scots safari park on market complete with five bed farmhouse and golf course

Adeline is also sister to nine-month-old twins, Josie and Jude.

Stephanie is charting Adelines journey on the Instagram feed @adelinebluesjourney_x and says messages of support there mean the world to the family.

We pay for your stories and videos! Do you have a story or video for The Scottish Sun? Email us at scoop@thesun.co.uk or call 0141 420 5300

Read the original:
Scots tot, 3, battling rare blood cancer to receive stem cell donations from anonymous American woman - The Scottish Sun